Serum S100B levels and major depressive disorder: Its characteristics and role in antidepressant response

Psychiatry Investigation

Volumn 5, Issue 3, 2008, Pages 193-198

  Jang, Byong Su ^a   Kim, Hyeren ^a   Lim, Shinn Won ^b   Jang, Ki Won ^b   Kim, Doh Kwan ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Antidepressant; Major depressive disorder; Neuroplasticity; Response; S100B

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; NEUROTROPHIC FACTOR; NORTRIPTYLINE; PAROXETINE; PROTEIN S100B; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NERVE CELL PLASTICITY; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

EID: 54549115958     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2008.5.3.193     Document Type: Article

References (42)

1. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109:143-148.
2. Duman RS. Synaptic plasticity and mood disorders. Mol Psychiatry 2002;7 Suppl 1: S29-34.
3. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008;33:88-109.
4. Daszuta A, Ban M Sr, Soumier A, Hery M, Mocaer E. Depression and neuroplasticity: implication of serotoninergic systems. Therapie 2005; 60:461-468.
5. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809.
6. Arantes-Goncalves F, Coelho R. Depression and treatment. Apoptosis, neuroplasticity and antidepressants. Acta Med Port 2006; 19:9-20.
7. Henkel AW, Sperling W, Rutter A, Reulbach U, Reichardt C, Bonsch D, et al. Antidepressant drugs modulate growth factors in cultured cells. BMC Pharmacol 2008;8:6.
8. Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008;320:385-388.
9. Marji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000;5:578-593.
10. Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21:134-140.
11. Ponath G, Schettler C, Kaestner F, Voigt B, Wentker D, Arch V, et al. Autocrine S100B effects on astrocytes are mediated via RAGE. J Neuroimmunol 2007;184:214-222.
12. Steiner J, Bernstein HG, Bielau H, Berndt A, Brisch R, Mawrin C, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007;8:2.
13. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637-668.
14. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 2006;396:201-214.
15. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995;37:417-429.
16. Schmitt KR, Kern C, Lange PE, Berger F, Abdul-Khaliq H, Hendrix S. S100B modulates IL-6 release and cytotoxicity from hypothermic brain cells and inhibits hypothermia-induced axonal outgrowth. Neurosci Res 2007;59:68-73.
17. Rothermundt M, Arolt V, Wiesmann M, Missler U, Peters M, Rudolf S, et al. S100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 2001;66:89-93.
18. Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE. S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport 2002; 13:1675-1678.
19. Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, et al. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 2003;13:235-239.
20. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Serum markers support disease-specific glial pathology in major depression. J Affect Disord. In press. 2008.
21. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuro-report 2000; 11:215-219.
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Association; 1994.
23. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
24. Kang Y, Na DL, Hahn S. A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients. J Korean Neurol Assoc 1997;15:300-308.
25. Ijuin M, Homma A, Mimura M, Kitamura S, Kawai Y, Imai Y, et al. Validation of the 7-Minute Screen for the detection of early-stage Alzheimer's disease. Dement Geriatr Cogn Disord 2008;25:248-255.
26. Ku HM, Lee HS. A study on the reliability and validity of Seoul-Activities of Daily Living (S-ADL). J Korean Geriatr Soc 2004;8:206-214.
27. Christensen KJ, Multhaup KS, Nordstrom S. A cognitive battery for dementia: development and measurement characteristics. J Consult Clin Psychol 1991;3:168-174.
28. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
29. Abdul-Khaliq H, Schubert S, Stoltenburg-Didinger G, Troitzsch D, Böttcher W, Hübler M, et al. Protein S-100beta in brain and serum after deep hypothermic circulatory arrest in rabbits: relationship to perivascular astrocytic swelling. Clin Chem Lab Med 2000;38:1169-1172.
30. Pinto SS, Gottfried C, Mendez A, Goncalves D, Karl J, Goncalves CA, et al. Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology. FEBS Lett 2000;486: 203-207.
31. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta 2004; 342:1-12.
32. Rothermundt M, Peters M, Prehn JH, Arolt S100B in brain damage and neurodegeneration. Microsc Res Tech 2003;60:614-632.
33. Kogel D, Peters M, König HG, Hashemi SM, Bui NT, Arolt V, et al. S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury. Neuroscience 2004;127:913-920.
34. Kleindienst A, McGinn MJ, Harvey HB, Colello RJ, Hamm RJ, Bullock MR. Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. J Neurotrauma 2005;22:645-655.
35. Hetzel G, Moeller O, Evers S, Erfurth A, Ponath G, Arolt V, et al. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology (Berl) 2005;178:161-166.
36. D'Sa C, Duman RS. Antidepressant and neuroplasticity. Bipolar Disord 2002;4:183-194.
37. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanism in the action of antidepressants: a critical overview. Pharmacol Rev 2006;58:115-134.
38. Lee HY, Kim YK. Plasma Brain-Derived Neurotrophic Factor as a Peripheral Marker for the Action Mechanism of Antidepressants. Neuropsychobiology 2008;57:194-199.
39. Whitaker-Azmitia PM, Murphy R, Azmitia EC. Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res 1990;528:155-158.
40. Carson MJ, nomas EA, Danielson PE, Sutcliffe JG. The 5HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: a mechanism for neuronal suppression of reactive astrocytes. Glia 1996;17:317-326.
41. Porter JT, McCarthy KD. Astrocytic neurotransmitter receptors in situ and in vivo. Prog Neurobiol 1997;51:439-455.
42. Paizanis E, Hamon M, Lanfumey L. Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. Neural Plast 2007;2007: 73754.